Protected: Tecentriq® (atezolizumab) + chemotherapy now TGA approved for 1L extensive-stage small cell lung cancer
Share.
About Author
Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
Related Posts
-
No added benefit of atezolizumab in post-surgical treatment of early-stage triple-negative breast cancer
-
Trial implies the addition of atezolizumab concurrently to standard of care does not improve survival in limited-stage small cell lung cancer
-
New metabolic signature predicts immunotherapy response and survival in bladder cancer